{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T10:15:23Z","timestamp":1776507323644,"version":"3.51.2"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:00:00Z","timestamp":1751414400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:00:00Z","timestamp":1751414400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Herz"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s00059-025-05324-y","type":"journal-article","created":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T08:35:44Z","timestamp":1751445344000},"page":"297-304","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Diagnose und Therapie der Herzinsuffizienz mit reduzierter Ejektionsfraktion","Diagnosis and treatment of heart failure with reduced ejection fraction"],"prefix":"10.1007","volume":"50","author":[{"given":"Samira","family":"Soltani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johann","family":"Bauersachs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,2]]},"reference":[{"key":"5324_CR1","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1093\/eurheartj\/ehaa1012","volume":"42","author":"J Bauersachs","year":"2021","unstructured":"Bauersachs\u00a0J (2021) Heart failure drug treatment: the fantastic four. Eur Heart\u00a0J 42:681\u2013683. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa1012","journal-title":"Eur Heart J"},{"key":"5324_CR2","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1055\/a-1760-3843","volume":"147","author":"S Soltani","year":"2022","unstructured":"Soltani\u00a0S, B\u00f6hm\u00a0M, Frey\u00a0N et\u00a0al (2022) Fr\u00fche Implementierung der \u201eFantastic four\u201c bei Herzinsuffizienz mit reduzierter Ejektionsfraktion. Dtsch Med Wochenschr 147:931\u2013938. https:\/\/doi.org\/10.1055\/a-1760-3843","journal-title":"Dtsch Med Wochenschr"},{"key":"5324_CR3","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.ijcard.2017.03.032","volume":"240","author":"DA Pascual-Figal","year":"2017","unstructured":"Pascual-Figal\u00a0DA, Ferrero-Gregori\u00a0A, Gomez-Otero\u00a0I et\u00a0al (2017) Mid-range left ventricular ejection fraction: clinical profile and cause of death in ambulatory patients with chronic heart failure. Int J Cardiol 240:265\u2013270. https:\/\/doi.org\/10.1016\/j.ijcard.2017.03.032","journal-title":"Int J Cardiol"},{"key":"5324_CR4","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1016\/j.jacc.2009.08.019","volume":"54","author":"SM Dunlay","year":"2009","unstructured":"Dunlay\u00a0SM, Redfield\u00a0MM, Weston\u00a0SA et\u00a0al (2009) Hospitalizations after heart failure diagnosis a community perspective. J\u00a0Am Coll Cardiol 54:1695\u20131702. https:\/\/doi.org\/10.1016\/j.jacc.2009.08.019","journal-title":"J Am Coll Cardiol"},{"key":"5324_CR5","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1186\/s12913-020-05828-9","volume":"20","author":"C Escobar","year":"2020","unstructured":"Escobar\u00a0C, Varela\u00a0L, Palacios\u00a0B et\u00a0al (2020) Costs and healthcare utilisation of patients with heart failure in Spain. BMC Health Serv Res 20:964. https:\/\/doi.org\/10.1186\/s12913-020-05828-9","journal-title":"BMC Health Serv Res"},{"key":"5324_CR6","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1002\/ejhf.516","volume":"18","author":"SD Anker","year":"2016","unstructured":"Anker\u00a0SD, Schroeder\u00a0S, Atar\u00a0D et\u00a0al (2016) Traditional and new composite endpoints in heart failure clinical trials: facilitating comprehensive efficacy assessments and improving trial efficiency. Eur J Heart Fail 18:482\u2013489. https:\/\/doi.org\/10.1002\/ejhf.516","journal-title":"Eur J Heart Fail"},{"key":"5324_CR7","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab368","author":"TA McDonagh","year":"2021","unstructured":"McDonagh\u00a0TA, Metra\u00a0M, Adamo\u00a0M et\u00a0al (2021) 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European society of cardiology (ESC) with the special contribution of the heart failure association (HFA) of the ESC. Eur Heart\u00a0J. https:\/\/doi.org\/10.1093\/eurheartj\/ehab368","journal-title":"Eur Heart J"},{"key":"5324_CR8","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1016\/s0140-6736(22)02076-1","volume":"400","author":"A Mebazaa","year":"2022","unstructured":"Mebazaa\u00a0A, Davison\u00a0B, Chioncel\u00a0O et\u00a0al (2022) Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a\u00a0multinational, open-label, randomised, trial. Lancet 400:1938\u20131952. https:\/\/doi.org\/10.1016\/s0140-6736(22)02076-1","journal-title":"Lancet"},{"key":"5324_CR9","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","volume":"44","author":"TA McDonagh","year":"2023","unstructured":"McDonagh\u00a0TA, Metra\u00a0M, Adamo\u00a0M et\u00a0al (2023) 2023 focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart\u00a0J 44:3627\u20133639. https:\/\/doi.org\/10.1093\/eurheartj\/ehad195","journal-title":"Eur Heart J"},{"key":"5324_CR10","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1056\/nejm199108013250501","volume":"325","author":"S Investigators","year":"1991","unstructured":"Investigators\u00a0S, Yusuf\u00a0S, Pitt\u00a0B et\u00a0al (1991) Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N\u00a0Engl J Med 325:293\u2013302. https:\/\/doi.org\/10.1056\/nejm199108013250501","journal-title":"N Engl J Med"},{"key":"5324_CR11","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1056\/nejm198706043162301","volume":"316","author":"CONSENSUS Trial Study Group","year":"1987","unstructured":"CONSENSUS Trial Study Group (1987) Effects of enalapril on mortality in severe congestive heart failure. N\u00a0Engl J Med 316:1429\u20131435. https:\/\/doi.org\/10.1056\/nejm198706043162301","journal-title":"N Engl J Med"},{"key":"5324_CR12","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/s0140-6736(03)14283-3","volume":"362","author":"JJ McMurray","year":"2003","unstructured":"McMurray\u00a0JJ, \u00d6stergren\u00a0J, Swedberg\u00a0K et\u00a0al (2003) Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 362:767\u2013771. https:\/\/doi.org\/10.1016\/s0140-6736(03)14283-3","journal-title":"Lancet"},{"key":"5324_CR13","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/s0140-6736(03)14284-5","volume":"362","author":"CB Granger","year":"2003","unstructured":"Granger\u00a0CB, McMurray\u00a0JJ, Yusuf\u00a0S et\u00a0al (2003) Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 362:772\u2013776. https:\/\/doi.org\/10.1016\/s0140-6736(03)14284-5","journal-title":"Lancet"},{"key":"5324_CR14","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/nejmoa1409077","volume":"371","author":"JJV McMurray","year":"2014","unstructured":"McMurray\u00a0JJV, Packer\u00a0M, Desai\u00a0AS et\u00a0al (2014) Angiotensin-neprilysin inhibition versus enalapril in heart failure. N\u00a0Engl J Med 371:993\u20131004. https:\/\/doi.org\/10.1056\/nejmoa1409077","journal-title":"N Engl J Med"},{"key":"5324_CR15","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1056\/nejm199605233342101","volume":"334","author":"M Packer","year":"1996","unstructured":"Packer\u00a0M, Bristow\u00a0MR, Cohn\u00a0JN et\u00a0al (1996) The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N\u00a0Engl J Med 334:1349\u20131355. https:\/\/doi.org\/10.1056\/nejm199605233342101","journal-title":"N Engl J Med"},{"key":"5324_CR16","doi-asserted-by":"publisher","unstructured":"Group M-HS (1999) Effect of metoprolol CR\/XL in chronic heart failure: Metoprolol CR\/XL Randomised Intervention Trial in-Congestive Heart Failure (MERIT-HF). Lancet 353:2001\u20132007. https:\/\/doi.org\/10.1016\/s0140-6736(99)04440-2","DOI":"10.1016\/s0140-6736(99)04440-2"},{"key":"5324_CR17","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/nejm199909023411001","volume":"341","author":"B Pitt","year":"1999","unstructured":"Pitt\u00a0B, Zannad\u00a0F, Remme\u00a0WJ et\u00a0al (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N\u00a0Engl J Med 341:709\u2013717. https:\/\/doi.org\/10.1056\/nejm199909023411001","journal-title":"N Engl J Med"},{"key":"5324_CR18","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/nejmoa1009492","volume":"364","author":"F Zannad","year":"2011","unstructured":"Zannad\u00a0F, McMurray\u00a0JJV, Krum\u00a0H et\u00a0al (2011) Eplerenone in patients with systolic heart failure and mild symptoms. N\u00a0Engl J Med 364:11\u201321. https:\/\/doi.org\/10.1056\/nejmoa1009492","journal-title":"N Engl J Med"},{"key":"5324_CR19","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/nejmoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray\u00a0JJV, Solomon\u00a0SD, Inzucchi\u00a0SE et\u00a0al (2019) Dapagliflozin in patients with heart failure and reduced ejection fraction. N\u00a0Engl J Med 381:1995\u20132008. https:\/\/doi.org\/10.1056\/nejmoa1911303","journal-title":"N Engl J Med"},{"key":"5324_CR20","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1161\/circulationaha.120.051783","volume":"143","author":"M Packer","year":"2021","unstructured":"Packer\u00a0M, Anker\u00a0SD, Butler\u00a0J et\u00a0al (2021) Effect of empagliflozin on the clinical stability of patients with heart failure and a\u00a0reduced ejection fraction. Circulation 143:326\u2013336. https:\/\/doi.org\/10.1161\/circulationaha.120.051783","journal-title":"Circulation"},{"key":"5324_CR21","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/s0140-6736(10)61198-1","volume":"376","author":"K Swedberg","year":"2010","unstructured":"Swedberg\u00a0K, Komajda\u00a0M, B\u00f6hm\u00a0M et\u00a0al (2010) Ivabradine and outcomes in chronic heart failure (SHIFT): a\u00a0randomised placebo-controlled study. Lancet 376:875\u2013885. https:\/\/doi.org\/10.1016\/s0140-6736(10)61198-1","journal-title":"Lancet"},{"key":"5324_CR22","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1056\/nejm199702203360801","volume":"336","author":"Digitalis Investigation Group","year":"1997","unstructured":"Digitalis Investigation Group (1997) The effect of digoxin on mortality and morbidity in patients with heart failure. N\u00a0Engl J Med 336:525\u2013533. https:\/\/doi.org\/10.1056\/nejm199702203360801","journal-title":"N Engl J Med"},{"key":"5324_CR23","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.3679","author":"U Bavendiek","year":"2025","unstructured":"Bavendiek\u00a0U et\u00a0al (2025) DIGitoxin to improve outcomes in patients with advanced chronic heart failure (DIGIT-HF): baseline characteristics compared to recent randomized controlled heart failure trials. Eur J Heart Fail. https:\/\/doi.org\/10.1002\/ejhf.3679","journal-title":"Eur J Heart Fail"},{"key":"5324_CR24","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1002\/ejhf.1452","volume":"21","author":"U Bavendiek","year":"2019","unstructured":"Bavendiek\u00a0U, Berliner\u00a0D, D\u00e1vila\u00a0LA et\u00a0al (2019) Rationale and design of the DIGIT-HF trial (DIGitoxin to Improve ouTcomes in patients with advanced chronic Heart Failure): a\u00a0randomized, double-blind, placebo-controlled study. Eur J Heart Fail 21:676\u2013684. https:\/\/doi.org\/10.1002\/ejhf.1452","journal-title":"Eur J Heart Fail"},{"key":"5324_CR25","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1002\/ejhf.3575","volume":"27","author":"U Bavendiek","year":"2025","unstructured":"Bavendiek\u00a0U, Berliner\u00a0D, Thomas\u00a0NH et\u00a0al (2025) The DIGIT-HF trial: key amendments of study design. Eur J Heart Fail 27:606\u2013608. https:\/\/doi.org\/10.1002\/ejhf.3575","journal-title":"Eur J Heart Fail"},{"key":"5324_CR26","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1056\/nejmoa1915928","volume":"382","author":"PW Armstrong","year":"2020","unstructured":"Armstrong\u00a0PW, Pieske\u00a0B, Anstrom\u00a0KJ et\u00a0al (2020) Vericiguat in patients with heart failure and reduced ejection fraction. N\u00a0Engl J Med 382:1883\u20131893. https:\/\/doi.org\/10.1056\/nejmoa1915928","journal-title":"N Engl J Med"},{"key":"5324_CR27","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1056\/nejm199108013250502","volume":"325","author":"JN Cohn","year":"1991","unstructured":"Cohn\u00a0JN, Johnson\u00a0G, Ziesche\u00a0S et\u00a0al (1991) A comparison of enalapril with hydralazine-Isosorbide dinitrate in the treatment of chronic congestive heart failure. N\u00a0Engl J Med 325:303\u2013310. https:\/\/doi.org\/10.1056\/nejm199108013250502","journal-title":"N Engl J Med"},{"key":"5324_CR28","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1056\/nejmoa042934","volume":"351","author":"AL Taylor","year":"2004","unstructured":"Taylor\u00a0AL, Ziesche\u00a0S, Yancy\u00a0C et\u00a0al (2004) Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N\u00a0Engl J Med 351:2049\u20132057. https:\/\/doi.org\/10.1056\/nejmoa042934","journal-title":"N Engl J Med"},{"key":"5324_CR29","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1038\/nrcardio.2015.109","volume":"12","author":"S von Haehling","year":"2015","unstructured":"von Haehling\u00a0S, Jankowska\u00a0EA, van Veldhuisen\u00a0DJ et\u00a0al (2015) Iron deficiency and cardiovascular disease. Nat Rev Cardiol 12:659\u2013669. https:\/\/doi.org\/10.1038\/nrcardio.2015.109","journal-title":"Nat Rev Cardiol"},{"key":"5324_CR30","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1056\/nejmoa0908355","volume":"361","author":"SD Anker","year":"2009","unstructured":"Anker\u00a0SD, Colet\u00a0JC, Filippatos\u00a0G et\u00a0al (2009) Ferric carboxymaltose in patients with heart failure and iron deficiency. N\u00a0Engl J Med 361:2436\u20132448. https:\/\/doi.org\/10.1056\/nejmoa0908355","journal-title":"N Engl J Med"},{"key":"5324_CR31","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1093\/eurheartj\/ehu385","volume":"36","author":"P Ponikowski","year":"2015","unstructured":"Ponikowski\u00a0P, van Veldhuisen\u00a0DJ, Comin-Colet\u00a0J et\u00a0al (2015) Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. Eur Heart\u00a0J 36:657\u2013668. https:\/\/doi.org\/10.1093\/eurheartj\/ehu385","journal-title":"Eur Heart J"},{"key":"5324_CR32","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1161\/circulationaha.117.027497","volume":"136","author":"DJ van Veldhuisen","year":"2017","unstructured":"van Veldhuisen\u00a0DJ, Ponikowski\u00a0P, van der Meer\u00a0P et\u00a0al (2017) Effect of ferric carboxymaltose on exercise capacity in patients with chronic heart failure and iron deficiency. Circulation 136:1374\u20131383. https:\/\/doi.org\/10.1161\/circulationaha.117.027497","journal-title":"Circulation"},{"key":"5324_CR33","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1016\/s0140-6736(20)32339-4","volume":"396","author":"P Ponikowski","year":"2020","unstructured":"Ponikowski\u00a0P, Kirwan\u00a0B\u2011A, Anker\u00a0SD et\u00a0al (2020) Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a\u00a0multicentre, double-blind, randomised, controlled trial. Lancet 396:1895\u20131904. https:\/\/doi.org\/10.1016\/s0140-6736(20)32339-4","journal-title":"Lancet"},{"key":"5324_CR34","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1016\/s0140-6736(22)02083-9","volume":"400","author":"PR Kalra","year":"2023","unstructured":"Kalra\u00a0PR, Cleland\u00a0JGF, Petrie\u00a0MC et\u00a0al (2023) Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial. Lancet 400:2199\u20132209. https:\/\/doi.org\/10.1016\/s0140-6736(22)02083-9","journal-title":"Lancet"},{"key":"5324_CR35","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2025.3833","author":"SD Anker","year":"2025","unstructured":"Anker\u00a0SD, Friede\u00a0T, Butler\u00a0J et\u00a0al (2025) Intravenous ferric carboxymaltose in heart failure with iron deficiency. JAMA. https:\/\/doi.org\/10.1001\/jama.2025.3833","journal-title":"JAMA"},{"key":"5324_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03671-1","author":"SD Anker","year":"2025","unstructured":"Anker\u00a0SD, Karakas\u00a0M, Mentz\u00a0RJ et\u00a0al (2025) Systematic review and meta-analysis of intravenous iron therapy for patients with heart failure and iron deficiency. Nat Med. https:\/\/doi.org\/10.1038\/s41591-025-03671-1","journal-title":"Nat Med"},{"key":"5324_CR37","doi-asserted-by":"publisher","first-page":"2771","DOI":"10.1093\/eurheartj\/ehae334","volume":"45","author":"C Veltmann","year":"2024","unstructured":"Veltmann\u00a0C, Duncker\u00a0D, Doering\u00a0M et\u00a0al (2024) Therapy duration and improvement of ventricular function in de novo heart failure: the heart failure optimization study. Eur Heart\u00a0J 45:2771\u20132781. https:\/\/doi.org\/10.1093\/eurheartj\/ehae334","journal-title":"Eur Heart J"}],"container-title":["Herz"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00059-025-05324-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00059-025-05324-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00059-025-05324-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T03:33:12Z","timestamp":1754623992000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00059-025-05324-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,2]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["5324"],"URL":"https:\/\/doi.org\/10.1007\/s00059-025-05324-y","relation":{},"ISSN":["0340-9937","1615-6692"],"issn-type":[{"value":"0340-9937","type":"print"},{"value":"1615-6692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,2]]},"assertion":[{"value":"14 May 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"Gem\u00e4\u00df den Richtlinien des Springer Medizin Verlags werden Autoren und Wissenschaftliche Leitung im Rahmen der Manuskripterstellung und Manuskriptfreigabe aufgefordert, eine vollst\u00e4ndige Erkl\u00e4rung zu ihren finanziellen und nichtfinanziellen Interessen abzugeben.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"J.\u00a0Bauersachs hat von Novartis, Vifor, Bayer, Servier, Abiomed, Pfizer, Boehringer Ingelheim, AstraZeneca, Cardior, Daichii Sankyo, CVRx, BMS, MSD, Amgen und Corvia Honorare f\u00fcr Vortrags- und Beratert\u00e4tigkeiten sowie Forschungsunterst\u00fctzung f\u00fcr die Institution von Zoll, CVRx, Vifor und Abiomed erhalten. S.\u00a0Soltani hat Honorare f\u00fcr Vortr\u00e4ge von AstraZeneca und KelCon erhalten. Es bestehen keine Interessenkonflikte im Zusammenhang mit diesem Artikel.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Autoren"}},{"value":"Die vollst\u00e4ndige Erkl\u00e4rung zum Interessenkonflikt der Wissenschaftlichen Leitung finden Sie am Kurs der zertifizierten Fortbildung auf .","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Wissenschaftliche Leitung"}},{"value":"erkl\u00e4rt, dass f\u00fcr die Publikation dieser CME-Fortbildung keine Sponsorengelder an den Verlag flie\u00dfen.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}}]}}